AstraZeneca Hits U.K. Antitrust Review with $39B Alexion Buy After U.S. FTC Clearance
May 25, 2021
Angus Liu
FiercePharma
Axinn partner Jeny Maier’s commentary was included in the FiercePharma article, "AstraZeneca Hits U.K. Antitrust Review with $39B Alexion Buy After U.S. FTC Clearance."
Click here to access the article.